Population pharmacokinetic modeling describes tirzepatide with a roughly 5-day half-life, supporting once-weekly dosing across the studied range, but the modeling itself is built on data from the 2.5/5/10/15 mg pen sizes
Ji L, Gao L, Xue H, et al
doi:10.3803/EnM.2024.1942 Lilly Investor Relations, News Release: Zepbound (tirzepatide) showed superior weight loss over Wegovy (semaglutide) in complete SURMOUNT-5 results published in The New England Journal of Medicine, May 11, 2025
If youre exploring weight loss options, the structured support and accountability provided by healthcare professionals at Rivas Medical Weight Loss can enhance your treatment success
In a post hoc analysis of the SUMMIT trial, the decrease in estimated blood volume seen in participants treated with tirzepatide was significantly correlated with decreased blood pressure, lower microalbuminuria, improved KCCQ-CSS, and greater 6-min walking distance [85]